Dutasteride
"Dutasteride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.
Descriptor ID |
D000068538
|
MeSH Number(s) |
D04.210.500.925.100.125
|
Concept/Terms |
Dutasteride- Dutasteride
- 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one
|
Below are MeSH descriptors whose meaning is more general than "Dutasteride".
Below are MeSH descriptors whose meaning is more specific than "Dutasteride".
This graph shows the total number of publications written about "Dutasteride" by people in this website by year, and whether "Dutasteride" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 0 | 1 | 1 | 2011 | 0 | 2 | 2 | 2012 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dutasteride" by people in Profiles.
-
Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer. 2013 Feb 01; 119(3):593-601.
-
Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24; 379(9821):1103-11.
-
Rove KO, Crawford ED. Dutasteride: novel milestones in prostate cancer chemoprevention. Drugs Today (Barc). 2011 Feb; 47(2):135-44.
-
Fern?ndez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, Levy EW, Solomon BI, Harris-Love MO, La Pean A, Schindler AB, Chen C, Di Prospero NA, Fischbeck KH. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb; 10(2):140-7.
-
Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|